# Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

> **NCT00283803** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 32 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Exisulind
- **DRUG:** luteinizing hormone-releasing hormone (LHRH) agonist
- **DRUG:** Antiandrogen

## Key facts

- **NCT ID:** NCT00283803
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283803, "Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00283803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*